8AP Stock Overview
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Agios Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$27.60 |
52 Week High | US$31.80 |
52 Week Low | US$18.80 |
Beta | 0.86 |
1 Month Change | 0% |
3 Month Change | 40.10% |
1 Year Change | 35.29% |
3 Year Change | -38.50% |
5 Year Change | -45.92% |
Change since IPO | 29.36% |
Recent News & Updates
Recent updates
Shareholder Returns
8AP | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -5.1% | -2.0% |
1Y | 35.3% | -21.1% | -0.3% |
Return vs Industry: 8AP exceeded the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: 8AP exceeded the German Market which returned -0.3% over the past year.
Price Volatility
8AP volatility | |
---|---|
8AP Average Weekly Movement | 8.7% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8AP's share price has been volatile over the past 3 months.
Volatility Over Time: 8AP's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 385 | Brian Goff | www.agios.com |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.
Agios Pharmaceuticals, Inc. Fundamentals Summary
8AP fundamental statistics | |
---|---|
Market cap | €1.56b |
Earnings (TTM) | -€330.54m |
Revenue (TTM) | €25.18m |
63.3x
P/S Ratio-4.8x
P/E RatioIs 8AP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
8AP income statement (TTM) | |
---|---|
Revenue | US$26.82m |
Cost of Revenue | US$298.41m |
Gross Profit | -US$271.58m |
Other Expenses | US$80.50m |
Earnings | -US$352.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | -6.27 |
Gross Margin | -1,012.50% |
Net Profit Margin | -1,312.63% |
Debt/Equity Ratio | 0% |
How did 8AP perform over the long term?
See historical performance and comparison